MediWound to Report First Quarter 2025 Financial Results

Core Viewpoint - MediWound Ltd. is set to report its financial results for Q1 2025 on May 21, 2025, and will host a conference call to discuss these results and provide corporate updates [1][2]. Company Overview - MediWound Ltd. is a global biotechnology company specializing in enzymatic therapies for non-surgical tissue repair. The company’s FDA-approved product, NexoBrid, is used for the enzymatic removal of eschar in thermal burns and is marketed in multiple regions including the U.S., EU, and Japan [3]. - The company is also developing EscharEx, a late-stage investigational therapy aimed at chronic wound debridement, which has shown clinical advantages over existing products and targets a significant global market opportunity [3]. Conference Call Details - The conference call and live webcast will take place at 8:30 a.m. Eastern Time on May 21, 2025. Participants can join via various dial-in numbers provided for toll-free, Israel, and international calls [2]. - An archived version of the webcast will be available for replay on the Investors section of the MediWound website [2]. Contact Information - MediWound has provided contact details for its Chief Financial Officer and Managing Director, as well as media contacts for further inquiries [5].